

PRELIMINARY AGENDA

- 9:00 WELCOME, OVERVIEW & OBRI PEARLS**
Dr. Claire Bombardier
- 9:20 ORAL POSTER:**
PATIENT REPORTED OUTCOMES PRE- AND DURING COVID
Dr. Matthew Wong-Pack
- 9:30 OBRI-RA COHORT UPDATE**
Dr. Bindee Kuriya, OBRI Clinical Advisory Committee
- 9:45 EXTENSION OF COMMUNITY HEALTHCARE OUTCOMES (ECHO) - RHEUMATOLOGY**
TBC
- 10:00 OBRI PSORIATIC ARTHRITIS COHORT UPDATE**
Dr. Sibel Aydin, OBRI Clinical Advisory Committee
- 10:15 ORAL POSTER:**
REAL-WORLD EFFECTIVENESS, SAFETY PROFILE, AND PERSISTENCE OF UPADACITINIB (RHUMADATA COLLABORATION)
Rhumadata
- 10:25 VACCINATION DATA COLLECTED BY OBRI INTERVIEWERS**
TBC
- 10:40 ORAL POSTER:**
RETENTION OF TRIPLE THERAPY WITH MTX, SSZ, HCQ COMPARED TO COMBINATION MTX AND LEFLUNOMIDE
Dr. Sankalp Bhavsar, OBRI Investigator
- 10:50 CPSO QUALITY IMPROVEMENT PROGRAM FOR SPECIALISTS (FOR CLINICIANS)**
Dr. Mary Manno and Dr. Ted Everson, College of Physicians and Surgeons of Ontario
- 11:20 CLOSING REMARKS**
Dr. Claire Bombardier

Continuing Education Credits for Rheumatologists

Rheumatologists participating as OBRI investigators may claim credits for performance assessment in Section 3, Royal College Maintenance of Certification (MOC) Program. Investigators who collect and complete the OBRI data collection tools, attend the OBRI Annual General Meeting and review / reflect on their individualized OBRI reports for self-improvement may record up to 25 hours (75 credits) for this program.